Tipsheet
What matters at India’s listed companies
Pharmaceuticals · Small cap

Gujarat Themis promoter stake is now tied to third-party debt

CTL Trusteeship discloses indirect encumbrance of the entire 47.02% promoter holding to secure debentures of OSS Software Solutions Labs, a previously undisclosed development that exposes the controlling block to enforcement risk.

4 earlier stories on Gujarat Themis Biosyn Ltd.
Mkt cap₹4,246 cr
P/E90.95×
ROE19.64%
Debt / eq.0.12
Div yld0.17%
47.02% Promoter stake now indirectly encumbered via pledge and NDU

What's new

  • Entire promoter holding of Gujarat Themis Biosyn indirectly encumbered as of 29 June 2026.
  • Vividhmargi Investments pledged 51% of PBGIL and gave NDU over another 47.99% for third-party debentures.
  • PBGIL holds the 47.02% promoter stake; the encumbrance secures debt of OSS Software Solutions Labs.

Why this matters

A clean promoter stake is now tied to unrelated debt. Though indirect, the disclosure signals promoter-level financial stress and could trigger a re-rating. For a small-cap with a ₹4,246 cr market cap and a pending Japan acquisition, this is a governance red flag.

What we're watching

  • Any further disclosure on the terms or size of OSS Software's debentures.
  • Whether the promoter clarifies if the encumbrance can be unwound before the QIP closes.
  • Market reaction at open, as the stock has no prior knowledge of this.

The full read

Gujarat Themis Biosyn's promoter block just got collateralised, and not for the company's own borrowing. CTL Trusteeship, as debenture trustee, disclosed that Vividhmargi Investments has pledged 51% of its stake in promoter entity PBGIL and given a non-disposal undertaking over another 47.99%, all to secure debentures of OSS Software Solutions Labs. Since PBGIL holds Themis's entire 47.02% promoter stake, the control is effectively tied to third-party debt. The encumbrance date was 29 June 2026, just days before the market learned of it. For a company raising equity for a ¥21.5 bn Japan deal, this is jarring. The ₹4,246 cr market cap now sits on a promoter stake that could be at risk if OSS defaults, a development the market never saw coming.

Questions answered

How much of Gujarat Themis is now encumbered?
The entire promoter stake of 47.02% is indirectly encumbered. Vividhmargi Investments pledged 51% of PBGIL and gave a non-disposal undertaking over another 47.99% of PBGIL, which holds the Themis shares.
Who is the money going to?
The encumbrance secures debentures issued by OSS Software Solutions Labs, a third party. It is not for Themis's own debt or the pending Japan acquisition.
Is this a direct pledge of Themis shares?
No, it is indirect, a pledge and NDU over shares of the promoter holding company PBGIL. But since PBGIL only holds Themis shares, the effect is the same.
What does this mean for the ongoing QIP for the Japan deal?
The encumbrance does not directly block the QIP, but it raises governance questions. Investors may demand clarity on promoter financial health before committing fresh equity.
Mentioned: CTL Trusteeship · Vividhmargi Investments · OSS Software Solutions Labs
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Gujarat Themis Biosyn Ltd.

Pharmaceuticals
₹4,277 cr
P/E 91.62×

Latest quarter · Mar 2026

Sales₹44 cr
Net profit₹11 cr
Op. margin+43.8%
EPS₹1.00

Strength & growth

Debt / equity0.12×
Current ratio1.84×
Sales CAGR+17.6%
EPS CAGR+26.0%
  1. 2 Jul 2026 · 8:19 AM IST Gujarat Themis promoter stake is now tied to third-party debt
  2. 27d ago Gujarat Themis will dilute a fifth of itself for a ¥21.5bn Japan deal
  3. 30d ago Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
  4. 39d ago Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
  5. 42d ago Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm